SymbioCellTech Demonstrates Preclinical Efficacy of Proprietary and Novel Human Neo-Islets^™ Technology in STZ-Diabetic NOD-SCID Mice

SymbioCellTech announced the publication of a paper demonstrating the potency and efficacy of its innovative and proprietary human Neo-Islet^™ in a third, clinically relevant model of human Type 1 Diabetes.